Shanghai Lingjiu Medical Technology Co., Ltd. has recently declared the triumphant conclusion of its Series A+ funding round, amassing tens of millions of yuan. This investment was jointly undertaken by Futeng Capital and Shanghai Fengxian Fund. The bulk of these funds will be earmarked for large-scale manufacturing, the establishment of a robust commercialization framework and sales network, all aimed at bolstering the introduction of its inaugural flagship product—a light-cured wound sealing adhesive. This product is anticipated to receive Class III medical device certification by 2026, paving the way for Lingjiu Medical to emerge as a frontrunner in the high-performance hydrogel materials sector.

Since its inception in 2017, Lingjiu Medical has swiftly positioned itself as a trailblazer in the realm of next-generation biomedical materials, thanks to its pioneering patented technologies. Its diverse business operations span across multiple domains. The company's R&D endeavors, spearheaded by Professor Lin Yong Zhu, have yielded a suite of innovative biomedical material products. Notably, the 'light-cured wound sealing adhesive' has embarked on the special approval pathway for national innovative medical devices.

Presently, Lingjiu Medical has achieved stable kilogram-scale production for select products, with several already making their mark in the commercial arena. Its premier offering, the light-cured wound sealing adhesive, is currently navigating the registration and supplementary application phase, with expectations to secure Class III medical device certification within the current year. Furthermore, the company has outlined plans to concurrently introduce a range of hydrogel profiles and disinfectant products, with the ambition of constructing a holistic, integrated platform enterprise.